Classifying Multimorbidity Using Drug Concepts via the Rx‐Risk Comorbidity Index: Methods and Comparative Cross‐Sectional Study
Authors' conclusion
The misclassification and under-ascertainment of comorbidities in single-specialty EHRs can largely be overcome by using a medication-focused comorbidity index.
Study context
- Population
- Established rheumatoid arthritis (RA) and osteoarthritis (OA) cohorts within the Rheumatology Informatics System for Effectiveness registry
- Exposure
- Rx-Risk vs Charlson Comorbidity Index, Rheumatic Disease Comorbidity Index (RDCI) and Elixhauser
- Outcome
- Comorbidity index score, RA cohort
Methodological detailsmethods development, comparative
- Methods development
- Comparative
Main finding
As reported in the abstract
Rx-Risk
6.00
median · IQR 2–9
Charlson
0
median · IQR 0–0
RDCI
0
median · IQR 0–0
Elixhauser
1
median · IQR 1–1
Observational data: associations, not effects.
Further findings
Mapping of drug concepts to Rx-Risk
- Unique ingredient RxCUIs representing the 46 Rx-Risk comorbidity categories
- 965
- Unique associated RxCUIs mapped (excluding dosage form and ingredient related RxCUIs)
- 80,911
- Unique National Drug Codes (NDCs) mapped
- 187,024
- Anatomical Therapeutic Chemical (ATC) codes mapped
- 354
Comorbidity index score, OA cohort
- Similar results to RA cohort
Patients with Charlson score of 0 (85% of total)
- Rx-Risk score range
- 0 to 16 or more
- RDCI and Elixhauser close to 1
Original publication
Classifying Multimorbidity Using Drug Concepts via the Rx‐Risk Comorbidity Index: Methods and Comparative Cross‐Sectional Study. Arthritis Care Res (Hoboken). Published 10 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →